Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

K A Aitbaev1, I T Murkamilov, V V Fomin

  • 1Research Institute of Molecular Biology and Medicine at the National Center of Cardiology and Therapy Named After acad. M. Mirrakhimov.. fake@neicon.ru.

Kardiologiia
|March 12, 2019
PubMed
Summary
This summary is machine-generated.

This review examines how lipid-lowering therapy impacts cardiovascular risk and kidney function in chronic kidney disease (CKD) patients. It highlights new treatments and nutritional advice for managing dyslipidemia in CKD.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Association of kidney dysfunction biomarkers with risk factors for development of chronic heart failure in middle-aged and elderly individuals.]

Advances in gerontology = Uspekhi gerontologii·2026
Same author

[Morphofunctional features of the left ventricle in patients with chronic cerebral ischemia].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
Same author

[Gastrointestinal bleeding after mitral valve implantation. Case report].

Terapevticheskii arkhiv·2026
Same author

[Gastrointestinal complications of dual antiplatelet therapy in patients with ischemic heart disease: risk stratification, current management tactics. A review].

Terapevticheskii arkhiv·2026
Same author

[Cardio-renal syndrome: perspectives of research in infectious diseases].

Terapevticheskii arkhiv·2026
Same author

[Association of the vertebral artery with cardiovascular disease risk factors in middle-aged and elderly individuals.]

Advances in gerontology = Uspekhi gerontologii·2026

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Chronic kidney disease (CKD) prevalence is rising, posing significant public health challenges.
  • CKD is linked to end-stage renal disease (ESRD) requiring costly treatments and increased cardiovascular disease (CVD) risk.
  • Hyper- and dyslipidemia significantly influence renal dysfunction progression and CVD development in CKD patients.

Purpose of the Study:

  • To review the effects of hypolipidemic therapy on cardiovascular risk reduction in CKD patients.
  • To evaluate the impact of lipid-lowering therapy on slowing renal dysfunction in pre-dialysis, dialysis, and kidney transplant patients.
  • To present current recommendations on nutrition, novel therapeutic approaches, and future prospects for lipid-lowering drugs in CKD.

Main Methods:

Related Experiment Videos

  • Systematic review of studies evaluating hypolipidemic therapy in CKD populations.
  • Analysis of data on cardiovascular risk and renal function changes.
  • Inclusion of nutritional recommendations and emerging therapeutic strategies.

Main Results:

  • Hypolipidemic therapy demonstrates potential in reducing cardiovascular risk in CKD patients.
  • Evidence suggests lipid-lowering interventions can slow the progression of renal dysfunction.
  • The review synthesizes findings across pre-dialysis, dialysis, and post-transplant stages.

Conclusions:

  • Lipid management is crucial for mitigating cardiovascular complications in CKD.
  • Hypolipidemic therapy offers a viable strategy for slowing CKD progression.
  • Future research should focus on novel lipid-lowering agents and personalized nutritional interventions for CKD.